Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.57 |
| ▸ | PREP | P48147 | 4/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL907262 | 1.00 | CHRM2 (0.57) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL15263195 | 0.86 | CHRM2 (0.55) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL372169 | 0.86 | CHRM2 (0.55) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL16040583 | 0.83 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL15934589 | 0.83 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL15934579 | 0.83 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL30438128 | 0.83 | CHRM2 (0.50) | CHRM2CHRM1CHRM3PREPHSD11B1 | |
| SCHEMBL6840077 | 0.81 | CHRM2 (0.32) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4385691 | 0.81 | CHRM2 (0.32) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4385689 | 0.81 | CHRM2 (0.32) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | HOKURIKU SEIYAKU CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1256582-A1 | 1H-IMIDAZOPYRIDINE DERIVATIVES | HOKURIKU SEIYAKU CO., LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054182-A1 | 1h-imidazopyridine derivatives | IL2, IL1A, IL4 | CHRM2 1646/4885CHRM1 666/4885CHRM3 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.